Professor Michael Good from the Institute for Glycomics, Griffith University |
Accepted into mBio, but available currently on MedRxiv, the research uses a mathematical epidemiological model to forecast the effect of childhood vaccination on the number of COVID-19 cases, hospitalizations, deaths, complications, and vaccine adverse effects in both children and in adults.
“Our model showed that childhood vaccination carries minimal risk, yet can result in large relative reductions in the disease” said Professor Michael Good from the Institute for Glycomics, Griffith University.
Professor Michael Good from the Institute for Glycomics, Griffith University
“For children between 5-11 years of age while we will see a high percent reduction in hospitalizations and deaths, there will not be a huge reduction in the actual number of children being hospitalized or dying because these events were so rare in the first place, even in unvaccinated children.”
The study showed that the biggest benefit of childhood vaccination will, perhaps surprisingly, be seen in adult populations.
“A critical point is that for children aged 5-11 cases of vaccine-associated myocarditis and anaphylaxis are predicted to be very rare, so childhood vaccination can be used altruistically to work for the greater population,” said Professor Michael Hawkes, School of Public Health, University of Alberta.